School of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Mov Disord Clin Pract. 2024 Jun;11(6):686-697. doi: 10.1002/mdc3.14044. Epub 2024 Apr 8.
Motor complications are well recognized in Parkinson's disease (PD), but their reported prevalence varies and functional impact has not been well studied.
To quantify the presence, severity, impact and associated factors for motor complications in PD.
Analysis of three large prospective cohort studies of recent-onset PD patients followed for up to 12 years. The MDS-UPDRS part 4 assessed motor complications and multivariable logistic regression tested for associations. Genetic risk score (GRS) for Parkinson's was calculated from 79 single nucleotide polymorphisms.
3343 cases were included (64.7% male). Off periods affected 35.0% (95% CI 33.0, 37.0) at 4-6 years and 59.0% (55.6, 62.3) at 8-10 years. Dyskinesia affected 18.5% (95% CI 16.9, 20.2) at 4-6 years and 42.1% (38.7, 45.5) at 8-10 years. Dystonia affected 13.4% (12.1, 14.9) at 4-6 years and 22.8% (20.1, 25.9) at 8-10 years. Off periods consistently caused greater functional impact than dyskinesia. Motor complications were more common among those with higher drug doses, younger age at diagnosis, female gender, and greater dopaminergic responsiveness (in challenge tests), with associations emerging 2-4 years post-diagnosis. Higher Parkinson's GRS was associated with early dyskinesia (0.026 ≤ P ≤ 0.050 from 2 to 6 years).
Off periods are more common and cause greater functional impairment than dyskinesia. We confirm previously reported associations between motor complications with several demographic and medication factors. Greater dopaminergic responsiveness and a higher genetic risk score are two novel and significant independent risk factors for the development of motor complications.
运动并发症在帕金森病(PD)中得到了很好的认识,但它们的报告患病率有所不同,其功能影响尚未得到很好的研究。
量化 PD 患者运动并发症的存在、严重程度、影响和相关因素。
对 3 项大型前瞻性队列研究的近期发病 PD 患者进行分析,这些患者的随访时间长达 12 年。MDS-UPDRS 第 4 部分评估了运动并发症,并通过多变量逻辑回归测试了关联。帕金森病的遗传风险评分(GRS)是由 79 个单核苷酸多态性计算得出的。
共纳入 3343 例患者(64.7%为男性)。在 4-6 年时,无运动障碍期占 35.0%(95%CI 33.0,37.0),在 8-10 年时占 59.0%(55.6,62.3)。异动症在 4-6 年时影响 18.5%(95%CI 16.9,20.2),在 8-10 年时影响 42.1%(38.7,45.5)。肌张力障碍在 4-6 年时影响 13.4%(12.1,14.9),在 8-10 年时影响 22.8%(20.1,25.9)。无运动障碍期比异动症造成更大的功能影响。在药物剂量较高、诊断年龄较小、女性、多巴胺能反应性较高(在挑战测试中)的患者中,运动并发症更为常见,这些关联在诊断后 2-4 年内出现。帕金森病的 GRS 较高与早期异动症有关(2 至 6 年时,0.026≤P≤0.050)。
无运动障碍期比异动症更常见,且对功能的损害更大。我们证实了运动并发症与一些人口统计学和药物因素之间的先前报告的关联。更大的多巴胺能反应性和更高的遗传风险评分是运动并发症发展的两个新的重要独立危险因素。